<DOC>
	<DOC>NCT00424983</DOC>
	<brief_summary>The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic acid during the previous 10-15 months.</brief_summary>
	<brief_title>Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male or female between 1875 years of age Multiple myeloma or breast cancer with bone involvement Treatment with zoledronic acid for bone lesions between 1015 months prior to entry into study with a total of 920 infusions received. Current active dental problems or recent (within 8 weeks) or planned dental or jaw surgery Active or uncontrolled infection, liver, or renal disease History of treatment with intravenous bisphosphonates Diagnosis of metabolic bone disorders other than osteoporosis (e.g. Paget's disease) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>